Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in ... PharmiWeb.com (press release) The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were ... Lilly pulls lymphoma drug enzastaurin after Phase III failure Another setback for Lilly as lymphoma drug fails Eli Lilly enzastaurin Phase III study fails to meet primary endpoint |
